Postdoctoral Research Scientist
Michelle's background is in molecular biology and genetics and her early career interests focused on investigations into the genetic causes of rare inherited retinal diseases. Since joining the University of Oxford on a Fight for Sight Junior Fellowship with St Cross College in 2010, she has progressed from trying to discover the causes of inherited retinal diseases to the treatment of such disorders. Michelle is currently the lead researcher on an MRC-funded project to develop an adeno-associated virus (AAV)-based gene therapy treatment for Stargardt disease, the most common cause of inherited childhood blindness. Stargardt disease is a progressive form of macular degeneration and so affects cells important for our central field of vision. Michelle's research aims to generate the pre-clinical data required to achieve a clinical trial for this gene therapy treatment over the next few years.
A fragmented adeno-associated viral dual vector strategy for treatment of diseases caused by mutations in large genes leads to expression of hybrid transcripts.
McClements ME. et al, (2016), J Genet Syndr Gene Ther, 7
Function of human pluripotent stem cell-derived photoreceptor progenitors in blind mice.
Barnea-Cramer AO. et al, (2016), Sci Rep, 6
Retention of cone function in a murine rhodopsin knock-out model of retinitis pigmentosa by rhodopsin gene delivery
Dauletbekov DL. et al, (2015), INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 56
Adeno-associated viral gene therapy for retinal disorders
de Silva SR. et al, (2015), Neuromethods, 98, 203 - 228
Gene Therapy for Retinal Disease
McClements ME. and MacLaren RE., (2014), Translating Gene Therapy to the Clinic: Techniques and Approaches, 173 - 189